Cipla looking to file more than 20 applications in US this fiscal

31 Jul 2017 Evaluate

Cipla is looking to file more than 20 applications seeking approval for its generic medicines from the US health regulator this fiscal. This step will be taken in order to strengthen the execution of its key launches, and building speciality focus in respiratory and Central Nervous System (CNS). The company had filed 32 abbreviated new drug applications (ANDAs) in the US in the last financial year.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.



Cipla Share Price

1434.60 0.00 (0.00%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×